Merck lands another Keytruda approval

Another ribbon-cutting for Keytruda

Merck is back in the FDA approval aisle again. The agency greenlit Keytruda and Keytruda Qlex, each paired with Gilead’s Trodelvy, for the first-line treatment of adult patients with PD-L1+ advanced triple-negative breast cancer.

That’s a mouthful, sure. But in investor-speak, it means Merck just added another approved use for the drug that has been carrying a suspiciously large share of the company’s oncology swagger.

Why you should care

Every new approved indication is basically a fresh room Keytruda can walk into and start billing in. Even for a mega-blockbuster like Merck’s crown jewel, more labels matter because they extend the drug’s runway and help cushion the eventual patent-cliff anxiety everyone keeps side-eyeing.

And Trodelvy’s role here matters too. This isn’t Merck going solo; it’s a combo play that reinforces how much big pharma growth now comes from stacking therapies like Lego bricks and hoping the final build is worth the price tag.

The big picture

For Merck, this is the kind of news that doesn’t usually make the stock do backflips, but it does keep the Keytruda machine humming. For Gilead, it’s another validation point for Trodelvy’s place in a major cancer regimen.

Big picture: if you own MRK, you’re not buying a sleepy pharma name — you’re buying a company that still finds new ways to stretch its blockbuster’s lifespan.